National Research Development Corporation

Geoffrey C Schild

David M Evans

Jeffrey W Almond

Philip D Minor

John Sidney Oxford

James S Robertson

Phillip D Minor

David A Tyrrell

Morag Ferguson

A strain of influenza virus, especially human influenza type A or B, for use in formulating a vaccine is selected by a process which comprises isolating candidate influenza viruses in embryonated hens' eggs, determining whether they have antigenic similarities to strains which are the same except that they have been isolated and grown exclusively in animal cells, that is to say whether they are 'cell-like', and selecting at least one such cell-like strain or a reassortant thereof having its HA and NA genes for the vaccine.

Influenza vaccine

A synthetic peptide, suitable for use in vaccination against or diagnosis of a disease caused by an enterovirus and especially by a poliovirus, is the peptide coded for by codons 286-290 in the RNA sequence coding for the structural capsid protein VP1 of poliovirus type 3 Sabin strain or by equivalent codons of another enterovirus or is an antigenic equivalent thereof, the numbers of the codons being counted from the 5'-terminus of the nucleotide sequence coding for the VP1 capsid protein.

Peptides useful in vaccination against enteroviruses

A synthetic polypeptide, suitable for use in vaccination against or diagnosis of a disease caused by an enterovirus, is an octapeptide coded for by codons 93-100 in the RNA sequence coded for the structural capsid protein VP1 for poliovirus type 3 Sabin strain or by equivalent codons of another enterovirus or is an antigenic equivalent of such an octapeptide, the numbers of the codons being counted from the 5'-terminus of the nucleotide sequence for the VP1 capsid protein.

Polypeptides useful in vaccination against enteroviruses

Growing community of inventors

London, United Kingdom

Geoffrey C Schild